Key result
SGLT2i reduces atherosclerotic events, HF hospitalizations, and CKD progression.
Why the study?
SGLT2 inhibitors have effects beyond glucose lowering, including cardiovascular and renal benefits, necessitating understanding of their mechanisms.
This review summarizes the mechanisms underlying the cardio-metabolic-renal benefits of SGLT2 inhibitors.
Reinforces the foundational role of SGLT2 inhibitors across the cardiore.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for treatment of diabetes, have been shown to possess a favorable metabolic profile and to significantly reduce atherosclerotic events, hospitalization for heart failure, cardiovascular and total mortality, and progression of chronic kidney disease. Although initially considered to be only glucose-lowering agents, the effects of SGLT2i have expanded far beyond that, and their use is now being studied in the treatment of heart failure and chronic kidney disease, even in patients without diabetes. It is therefore critical for cardiologists, diabetologists, nephrologists, and primary care physicians to be familiar with this drug class. This first part of this 2-part review provides an overview of the current understanding of the mechanisms of the cardio-metabolic-renal benefits of SGLT2i. The second part summarizes the recent clinical trials of SGLT2i.
No takes yet. Share an insight, caveat, or question.
Zelniker et al. (2020) conducted a review in Diabetes, heart failure, and chronic kidney disease. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) was evaluated. Sodium-glucose cotransporter 2 inhibitors provide cardio-metabolic-renal benefits, reducing atherosclerotic events, heart failure hospitalizations, and chronic kidney disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: